Stocks · News reference
B of A Securities analyst Jason Gerberry maintains Liquidia (NASDAQ:LQDA) with a Neutral and raises the price target from $79 to $92.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Liquidia's lead drug Yutrepia has gained significant market traction with over 5,000 patients started on therapy as of July 2026, but the stock has underperformed due to heavy reliance on a single product, ongoing patent litigation with United Therapeutics, competitive pressures, and rising R&D costs. Analysts recommend avoiding the stock due to an unfavorable risk-reward profile.
Liquidia stock rises after the FDA grants Fast Track status to YUTREPIA for treating Raynaud’s phenomenon in systemic sclerosis.
Filed: 2026-09-03 AccNo: 0001104659-26-104929 Size: 215 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that the U.S. Food